5th Neoantigen Summit Europe

Memo

Weaponising Truly Individualised TherapiesFor the first time in over two years, we're delighted to be reuniting the neoantigen community in person for the 5th Neoantigen Summit Europe, dedicated to the robust prediction, identification and validation of neoantigens.Pioneers in this exclusive industry are convening in Amsterdam this April to network and learn from experts in pharma, biotech and academia. Join us for exclusive discussions around shared and personalised neoantigens and discover the full potential of neoantigens in creating truly individualised cancer therapeutics.From understanding the latest clinical insights to defining and characterising the best epitopes, reviewing vaccines post-COVID to exploring emerging investment in foreign tumour antigens, our 3-day agenda is packed with dedicated content to help you increase precision of high quality neoantigen target identification.Find out more: https://ter.li/ibzkf4URLs:Brochure: https://go.evvnt.com/985806-0?pid=5569Tickets: https://go.evvnt.com/985806-2?pid=5569Prices:Early Bird 1 - FULL ACCESS PASS: Conference + Seminar Day - Drug Developer Pricing (Save €1,150): EUR 2996.0,Early Bird 1 - Conference Only - Drug Developer Pricing (Save €700): EUR 2099.0,Early Bird 1 - Seminar Day Only - Drug Developer Pricing (Save €550): EUR 1197.0,Early Bird 1 - FULL ACCESS PASS: Conference + Seminar Day - Solution/Service Provider Pricing (Save €1,150): EUR 4946.0,Early Bird 1 - Conference Only - Solution/Service Provider Pricing (Save €700): EUR 3299.0,Early Bird 1 - FULL ACCESS PASS: Conference + Seminar Day - Academic Pricing (Save €1,000): EUR 3296.0,Early Bird 1 - Conference Only - Academic Pricing (Save €700): EUR 2399.0,Early Bird 1 - Seminar Day Only - Academic Pricing (Save €400): EUR 1297.0Speakers: Agnete Fredriksen Chief Innovation and Strategy Officer Vaccibody, Andrew Allen CEO Gritstone bio, Aude-Helene Capietto Senior Principal Scientific Researcher, Cancer Immunology Genentech, Barbara Loesch Head of Technology and Innovation Medigene, David Gfeller Assistant Professor University of Lausanne, Elisa Scarselli Chief Scientific Officer Nouscom Srl, Eric Halioua President and CEO PDC*line Pharma, Erik Wiklund Chief Executive Officer Targovax ASA, Florian Kast Postdoctoral Researcher Roche, Guido Leoni Head of Bioinformatics Nouscom Srl, Heinrich Haas Vice President Formulation and Drug Development BioNTech AG, Heinz Lubenau Chief Executive Officer and Co-Founder Vaximm GmbH, Hugh Salter Chief Scientific Officer Anocca AB, Jean-Marc Limacher Co-Founder, President and Chief Medical Officer Odimma therapeutics, Jeffrey Bockman Executive Vice President and Oncology Practice Head Cello Health BioConsulting, Jens Kringelum Director, Genomic Immuno-Oncology Evaxion Biotech, Jeroen van Bergen Chief Scientific Officer Immunetune, Jessica Matta Co-Founder and Chief Executive Officer and Chief Scientific Officer Odimma therapeutics, Kaidre Bendjama Project Leader - Personalised Cancer Vaccines Transgene, Kostas Kosmatopoulos CEO Vaxon Biotech, Lone Ottesen Chief Medical Officer Targovax, Matthew Davies Head Of Bioinformatics Enara Bio, Maximilian Bosch Project Manager Lung Center, Cantonal Hospital St.Gallen, Switzerland, Nicola Ternette Principle Investigator, Antigen Discovery University of Oxford, Peter Joyce Chief Executive Officer and Co-founder Grey Wolf Therapeutics Ltd., Peter Sondermann CEO Tacalyx GmbH, Philip Arlen President and Chief Executive Officer Precision BioLogic, Sari Pesonen Co-Founder and Chief Scientific Officer Valo Therapeutics, Sijme Zeilemaker Founder and Chairman Immunetune, Stephane Depil Onco-Hematology Specialist Immuno-Oncology and Cancer Immunotherapy Centre Leon Berard, Thomas Sandal CTO R and D PokeAcell, Wigard Kloosterman Chief Scientific Officer Frame Frame TherapeuticsDate and Time: On Tuesday April 26, 2022 at 8:50 am (ends Thursday April 28, 2022 at 4:30 pm)Venue Details: Leonardo Royal Hotel Amsterdam, 24 Paul van Vlissingenstraat, Amsterdam, Noord-Holland, 1096 BK, Netherlands